Can a new immunotherapy combo outsmart advanced lung cancer?
NCT ID NCT05758116
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This phase II trial is testing whether the immunotherapy drug tislelizumab can help control locally advanced non-small cell lung cancer when given after radiation therapy or sequential chemoradiation. The study enrolls people with stage III lung cancer who cannot tolerate the standard concurrent chemoradiation and have not progressed after initial treatment. Participants receive tislelizumab every three weeks for about a year, and researchers will track how long they live without the cancer progressing, overall survival, and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab, an immunotherapy drug given intravenously every three weeks for about a year
- What this could lead to
- If it works, this could offer a new treatment option for people with locally advanced lung cancer who cannot tolerate standard concurrent chemoradiation, potentially helping to delay cancer progression.
- What could go wrong
- This is a small, early-phase trial with only 5 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the treatment may not improve outcomes for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONSOLIDATION IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital and Institute
Beijing, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Herbal extract may ease the toll of lung cancer immunotherapy